Security key
67080T108
Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (NVCT)
CUSIP: 67080T108
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Total 13F shares
- 10,235,371
- Total 13F value
- $188,749,483
- Share change
- +5,722,743
- Put/Call ratio
- 17%
- SEC-reported price per share
- $18.39
- Number of holders
- 81
- Value change
- +$105,650,549
- Number of buys
- 62
- Number of sells
- 16
- Shares outstanding
- 32,314,196
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
81
Top holders
10
NVCT full security history
Ownership snapshot
Full 13F holder table
Nuvectis Pharma, Inc. SEC filings
Nuvectis Pharma, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of NVCT - Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ron Bentsur
Disclosed value leader
Ron Bentsur
Comparable rows
15/15
Latest evidence
30 Jun 2026
3/4/5
13F
Lead comparable stake: 11%
Showing 1-6 of 15 holder rows.
Quick read
Ron Bentsur leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ron Bentsur's linked filing trail.
Comparable ownership
Top 5
Ron Bentsur
11%
Marlio Charles Mosseri
10%
Enrique Poradosu
5.6%
Shay Shemesh
5.5%
Kenneth Hoberman
0.52%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ron Bentsur |
3/4/5
Chairman & CEO, Director, 10%+ Owner
|
11%
|
$73,768,480
3,688,424 shares
|
+$278,600 | 30 Jun 2026 |
| Marlio Charles Mosseri |
3/4/5
10%+ Owner
|
10%
|
$59,223,123
3,295,897 shares
|
+$1,873,083 | 30 Jun 2026 |
| Enrique Poradosu |
3/4/5
Chief Science & Business Off
|
5.6%
|
$13,637,527
1,806,319 shares
|
— | 06 Jan 2026 |
| Shay Shemesh |
3/4/5
Chief Dev. & Ops. Officer
|
5.5%
|
$13,537,484
1,793,068 shares
|
— | 06 Jan 2026 |
| Kenneth Hoberman |
3/4/5
Director
|
0.52%
|
$1,299,722
168,140 shares
|
— | 11 Jun 2026 |
| Matthew L. Kaplan |
3/4/5
Director
|
0.49%
|
$1,234,944
159,760 shares
|
+$64,240 | 11 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
81
Shares
10,235,371
Rows available
81
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
62
Q2 2026 holders
81
Holder diff
19
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|